Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 203

1.

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.

Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, Agate L, Vivaldi A, Faviana P, Basolo F, Miccoli P, Berti P, Pacini F, Pinchera A.

J Clin Endocrinol Metab. 2008 Mar;93(3):682-7. Epub 2007 Dec 11.

PMID:
18073307
2.

Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas.

Dvorakova S, Vaclavikova E, Sykorova V, Vcelak J, Novak Z, Duskova J, Ryska A, Laco J, Cap J, Kodetova D, Kodet R, Krskova L, Vlcek P, Astl J, Vesely D, Bendlova B.

Mol Cell Endocrinol. 2008 Mar 12;284(1-2):21-7. doi: 10.1016/j.mce.2007.12.016. Epub 2008 Jan 8.

PMID:
18282654
3.

Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification.

Mian C, Pennelli G, Barollo S, Cavedon E, Nacamulli D, Vianello F, Negro I, Pozza G, Boschin IM, Pelizzo MR, Rugge M, Mantero F, Girelli ME, Opocher G.

Eur J Endocrinol. 2011 Jun;164(6):971-6. doi: 10.1530/EJE-11-0079. Epub 2011 Mar 21.

4.

Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma.

Marsh DJ, Learoyd DL, Andrew SD, Krishnan L, Pojer R, Richardson AL, Delbridge L, Eng C, Robinson BG.

Clin Endocrinol (Oxf). 1996 Mar;44(3):249-57.

PMID:
8729519
5.

Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon.

Boichard A, Croux L, Al Ghuzlan A, Broutin S, Dupuy C, Leboulleux S, Schlumberger M, Bidart JM, Lacroix L.

J Clin Endocrinol Metab. 2012 Oct;97(10):E2031-5. doi: 10.1210/jc.2012-2092. Epub 2012 Aug 3.

6.

CGH alterations in medullary thyroid carcinomas in relation to the RET M918T mutation and clinical outcome.

Frisk T, Zedenius J, Lundberg J, Wallin G, Kytölä S, Larsson C.

Int J Oncol. 2001 Jun;18(6):1219-25.

PMID:
11351254
7.

Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.

Komminoth P, Kunz EK, Matias-Guiu X, Hiort O, Christiansen G, Colomer A, Roth J, Heitz PU.

Cancer. 1995 Aug 1;76(3):479-89.

8.

Low prevalence of the somatic M918T RET mutation in micro-medullary thyroid cancer.

Romei C, Ugolini C, Cosci B, Torregrossa L, Vivaldi A, Ciampi R, Tacito A, Basolo F, Materazzi G, Miccoli P, Vitti P, Pinchera A, Elisei R.

Thyroid. 2012 May;22(5):476-81. doi: 10.1089/thy.2011.0358. Epub 2012 Mar 9.

PMID:
22404432
9.

Prognostic value of codon 918 (ATG-->ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma.

Schilling T, Bürck J, Sinn HP, Clemens A, Otto HF, Höppner W, Herfarth C, Ziegler R, Schwab M, Raue F.

Int J Cancer. 2001 Jan 20;95(1):62-6.

10.

Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma.

Ciampi R, Romei C, Cosci B, Vivaldi A, Bottici V, Renzini G, Ugolini C, Tacito A, Basolo F, Pinchera A, Elisei R.

Mol Cell Endocrinol. 2012 Jan 2;348(1):176-82. doi: 10.1016/j.mce.2011.08.004. Epub 2011 Aug 16.

PMID:
21867742
11.

Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas.

Moura MM, Cavaco BM, Pinto AE, Domingues R, Santos JR, Cid MO, Bugalho MJ, Leite V.

Br J Cancer. 2009 Jun 2;100(11):1777-83. doi: 10.1038/sj.bjc.6605056. Epub 2009 Apr 28.

12.

Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence.

Romei C, Elisei R, Pinchera A, Ceccherini I, Molinaro E, Mancusi F, Martino E, Romeo G, Pacini F.

J Clin Endocrinol Metab. 1996 Apr;81(4):1619-22.

PMID:
8636377
13.

Mutation of the RET proto-oncogene is correlated with RET immunostaining in subpopulations of cells in sporadic medullary thyroid carcinoma.

Eng C, Thomas GA, Neuberg DS, Mulligan LM, Healey CS, Houghton C, Frilling A, Raue F, Williams ED, Ponder BA.

J Clin Endocrinol Metab. 1998 Dec;83(12):4310-3.

PMID:
9851769
14.

Somatic mutations in RET exons 12 and 15 in sporadic medullary thyroid carcinomas: different spectrum of mutations in sporadic type from hereditary type.

Uchino S, Noguchi S, Yamashita H, Sato M, Adachi M, Yamashita H, Watanabe S, Ohshima A, Mitsuyama S, Iwashita T, Takahashi M.

Jpn J Cancer Res. 1999 Nov;90(11):1231-7.

PMID:
10622534
15.

Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series.

Ciampi R, Mian C, Fugazzola L, Cosci B, Romei C, Barollo S, Cirello V, Bottici V, Marconcini G, Rosa PM, Borrello MG, Basolo F, Ugolini C, Materazzi G, Pinchera A, Elisei R.

Thyroid. 2013 Jan;23(1):50-7. doi: 10.1089/thy.2012.0207. Epub 2012 Dec 16.

PMID:
23240926
16.

Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma.

Eng C, Mulligan LM, Smith DP, Healey CS, Frilling A, Raue F, Neumann HP, Ponder MA, Ponder BA.

Clin Endocrinol (Oxf). 1995 Jul;43(1):123-7.

PMID:
7641404
17.

New multiple somatic mutations in the RET proto-oncogene associated with a sporadic medullary thyroid carcinoma.

Dvoráková S, Václavíková E, Sýkorová V, Dusková J, Vlcek P, Ryska A, Novák Z, Bendlová B.

Thyroid. 2006 Mar;16(3):311-6.

PMID:
16571096
18.

RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.

Elisei R, Romei C, Cosci B, Agate L, Bottici V, Molinaro E, Sculli M, Miccoli P, Basolo F, Grasso L, Pacini F, Pinchera A.

J Clin Endocrinol Metab. 2007 Dec;92(12):4725-9. Epub 2007 Sep 25.

PMID:
17895320
19.

Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.

Ciampi R, Romei C, Pieruzzi L, Tacito A, Molinaro E, Agate L, Bottici V, Casella F, Ugolini C, Materazzi G, Basolo F, Elisei R.

J Endocrinol Invest. 2017 Jan;40(1):55-62. doi: 10.1007/s40618-016-0526-5. Epub 2016 Aug 17.

PMID:
27535135
20.

High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas.

Simbolo M, Mian C, Barollo S, Fassan M, Mafficini A, Neves D, Scardoni M, Pennelli G, Rugge M, Pelizzo MR, Cavedon E, Fugazzola L, Scarpa A.

Virchows Arch. 2014 Jul;465(1):73-8. doi: 10.1007/s00428-014-1589-3. Epub 2014 May 15.

PMID:
24828033

Supplemental Content

Support Center